Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Investigators analyzed the degree to which various factors predicted ischemic and hemorrhagic strokes in this population.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.
Large European study finds that more than 1 in 10 people with HIV acquire HCV again.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
CANN will present its annual report on the state of co-infection in the United States.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
Pharmacists oversaw the delivery of hepatitis C treatment in a recent study.
European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.
A study of gay and bi men with HIV in Australia who had been cured of hep C found they associated hep C with injection drug use.
Chronic inflammation is associated with numerous harms.
Better antiretrovirals have likely mitigated HIV’s effects on the risk of end-stage liver disease and liver cancer in those with hep C.
Researchers used mathematical modeling to analyze the benefits of treating with buprenorphine/naloxone on-site.
Four things you should know to be #HepAware.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.